Fundación Valle del Lili

Cali 760033

3 studies enrolling now · 8 studies all time

What they study most

Crohn's Disease, Heart Failure, Hemorrhage, Indolent Systemic Mastocytosis, Inflammatory Bowel Diseases, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol, Proteinuric Kidney Disease, Secondary Prevention, Smoldering Systemic Mastocytosis, Stroke

Studies at this site

• (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis — Recruiting now
• Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease — Recruiting now
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Reversal of Dabigatran Anticoagulant Effect With Idarucizumab — Completed